New combo aims to shrink rectal tumors without surgery

NCT ID NCT07162714

Recruiting now Disease control Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new approach for patients with a specific type of mid-low rectal cancer (pMMR/MSS). Participants receive a short course of radiation followed by six cycles of the immunotherapy drug ivonescimab. The goal is to see if this combination can make the cancer disappear completely, potentially allowing some patients to avoid surgery and adopt a 'watch and wait' strategy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab (AK112)
What this could lead to: If successful, this combination could offer a non-surgical option for some patients with mid-low rectal cancer, potentially avoiding the need for major surgery.
What could go wrong: This is a small, early-phase study with only 30 participants. The treatment may not work as hoped, and side effects from the combination of radiation and immunotherapy could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AK112 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

radiation injury rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AK112 RADIATION RECTAL CANCER

Contacts and locations

Locations

Zhejiang cancer hosptial
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.